Extended kinase profile and properties of the protein kinase inhibitor nilotinib - Wikidata - wikimedia - TriplyDB

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

http://www.wikidata.org/entity/Q28265109

about

Lung inflammation caused by inhaled toxicants: a review Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing Structure of the Human Protein Kinase ZAK in Complex with Vemurafenib Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.Targeting Plasmodium PI(4)K to eliminate malaria A computational approach to finding novel targets for existing drugs Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells SRChing for the substrates of Src.Ponatinib reduces viability, migration, and functionality of human endothelial cells.Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis Ricin Toxin Activates the NALP3 Inflammasome.Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo Identification of autophosphorylation inhibitors of the inositol-requiring enzyme 1 alpha (IRE1α) by high-throughput screening using a DELFIA assay.ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells.Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.KINATEST-ID: a pipeline to develop phosphorylation-dependent terbium sensitizing kinase assays.Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial Nilotinib protects the murine liver from ischemia/reperfusion injury.Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model.Shiga toxin 2-induced intestinal pathology in infant rabbits is A-subunit dependent and responsive to the tyrosine kinase and potential ZAK inhibitor imatinib Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models Activation of abl family kinases in solid tumors.Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin.Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation.Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression Surgical resection of recurrent gastrointestinal stromal tumor after interruption of long-term nilotinib therapy.Nilotinib: a novel, selective tyrosine kinase inhibitor.Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.

P2860

Q26744356-EB22D2BA-AF10-438A-89E5-61E8ADFB406F Q26751285-5B8386A1-0865-4374-ABE0-E189EB9ACAC1 Q27644421-CECCC407-AD09-4DCE-BB75-AEADDA843AB0 Q27660281-10451910-889A-41EF-8A87-533D116C4AA1 Q27666758-7F9C5E6A-5550-4317-9D8D-A9DDCAE72A76 Q27704282-4D273D5E-CE83-4FA1-91D7-5C7BEF78126D Q27851720-5AF30DF0-8614-4B2D-9A14-7F9854901AB2 Q27974482-2FBEDBC2-CB46-4106-BCA6-C9B23318E48C Q28476770-45901EA7-7D75-4D88-8EEA-BA511C99461F Q28483929-B8689D71-540F-4FD6-9ECF-B14A5C1824B2 Q28534337-B4971B4A-F627-4BFA-AF24-EB673F2A72AD Q28728224-3E70DF67-8E81-4537-9BC8-570E893C3D1D Q30457060-902ECEEC-E4B6-4683-8031-DCE9E61879A8 Q33364077-1FFB2DD9-6251-47A2-9219-E9EF468E4DD8 Q33394812-64A05E9A-BB82-4B60-A237-B9FCCE6F27DE Q33399867-358BCE79-69D7-4E5A-BA76-E8DFA7B48C78 Q33401360-8FC384AA-8968-4FF3-94E5-E78C4A280131 Q33423072-E7230FFE-4B71-4A67-8759-4681E94A839D Q33677805-81BBFF6D-B324-4DFE-BA81-316D6794E36E Q34141940-AC93CBA4-F2CB-4805-9B4E-BFF8DC4FC765 Q34395057-19182D4B-DF80-4FC0-A365-04A0B7151E94 Q34471638-7A6599AD-45A9-4507-93A7-7B6A8BE9A6A1 Q34581761-9A8EAE59-C663-4566-9C2F-AC39C3AABDE6 Q34894883-BC15CDE4-209B-47BE-BF29-01926D028704 Q35125933-B7172652-6452-4961-B594-48401A7D6AFE Q35252470-AB731E30-CCB2-4A09-A533-C1CD1F3C506F Q35905878-B3098DAD-3623-4601-9E4E-D4E8FE275AC7 Q35961706-246BECAF-F547-42DA-948B-05DA6AFEE438 Q36219461-AD641BEB-6E30-450C-BF47-9EF0F9AD34CA Q36316869-7FAA348C-B2CD-49E9-8DD7-5B093F56B480 Q36382092-B3F0DF24-3CFD-43A5-9027-5656374796C3 Q36442931-3D7B85CE-42EE-4330-8F53-969C7141828D Q36443421-D87A3271-A821-4CC9-87B1-1F5A8AC8BC75 Q36591937-F3EF90E2-B1BC-4642-8155-EC9A51F02ADC Q36947802-CB050085-B62E-44F2-9A49-BD0F49724804 Q37137895-205C6C31-C887-4226-8DD4-61764826615E Q37142455-9C063671-30E6-435A-9D77-B9D5AC986E80 Q37423620-91141B1B-007D-42AC-A3B7-28BB051A5FE6 Q37855073-18105ACC-6570-4A24-A3CD-075B5CB9C9BB Q37958678-18AB28A4-9BA3-4C34-9C34-2328E206C753

P2860

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

http://www.wikidata.org/entity/Q28265109

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

@ast

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

@en

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

@nl

type

label

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

@ast

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

@en

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

@nl

prefLabel

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

@ast

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

@en

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

@nl

P1433

Q28265109-45ABE4A5-B867-4388-ABA3-CBABDF0EA870

P1476

Q28265109-2329E644-4406-472C-9098-79872D141245

P2093

Q28265109-235E3203-2015-428B-B57B-89DE9743BE17

Q28265109-28B6C0BF-F809-4AC7-AE44-F38B42640F38

Q28265109-2987261E-9E98-43D5-9D58-8A7207920BAD

Q28265109-3B1556C8-EB81-40BD-9D1C-9669B40618EF

Q28265109-3F68EB05-C1B2-4B2B-9834-317A44AEC7A3

Q28265109-44DCAF77-EBD0-413E-BFDC-6BB1516026E4

Q28265109-77D6A2CA-FF01-4E34-B4C1-70D1A09AF461

Q28265109-89C121EA-3F74-4E06-B583-1BB507C76DA3

Q28265109-97F6996F-208E-42EA-93FB-28C340EE1907

Q28265109-E45CDE77-C7F9-4163-B6F4-5C5A6EC128EC

P304

Q28265109-5B7BFDDE-A757-4671-BEED-8D3F12108B0F

P31

Q28265109-A6D7C164-B407-409C-9862-03E684FFA93A

P3181

Q28265109-AFB11BC9-7F17-45EA-B949-26FCBAB1D493

P356

Q28265109-6830DBF1-2AA7-4780-823F-162AEBB0D0B3

P407

Q28265109-04D265F5-CB75-444A-B928-B632AE99ED95

P433

Q28265109-320B6D52-FF12-43AC-BD7A-EB0DBE6CE3F8

P478

Q28265109-803439CF-1B25-476C-874F-8718841DB25D

P577

Q28265109-338D3981-E23E-4F14-9B7E-56245C0AD21C

P698

Q28265109-93687FB4-5A24-4D53-B152-A586A6F6EB7A

P3181

P356

J.BBAPAP.2009.11.008

P1433

Biochimica et Biophysica Acta

P1476

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

@en

P2093

Doriano Fabbro

http://www.w3.org/2001/XMLSchema#string

Gabriele Fendrich

http://www.w3.org/2001/XMLSchema#string

Georg Martiny-Baron

http://www.w3.org/2001/XMLSchema#string

Janis Liebetanz

http://www.w3.org/2001/XMLSchema#string

Jörg Trappe

http://www.w3.org/2001/XMLSchema#string

Jürgen Mestan

http://www.w3.org/2001/XMLSchema#string

Markus Wartmann

http://www.w3.org/2001/XMLSchema#string

Pascal Furet

http://www.w3.org/2001/XMLSchema#string

Paul W Manley

http://www.w3.org/2001/XMLSchema#string

Peter Drueckes

http://www.w3.org/2001/XMLSchema#string

P304

445-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

549643

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.BBAPAP.2009.11.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1804

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19922818

http://www.w3.org/2001/XMLSchema#string